Next, three types of Claudin18.2-positive HLA-A*0201 GC cell lines (NUGC4, AGS, and KE39, Figure S1A–C) were used to test the anti-tumor ability of 118–126 peptide-specific T cells by CFSE/PI labeling cytotoxicity assay. This evidence concerns the gene HLA-A and neoplasm.